Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Velcade added to Adriamycin-Dexamethasone versus VAD in relapsed or refractory multiple myeloma
2006-001709-27Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2006
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bortezomib in multiple myeloma (MM) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Response rate. Started Jun 2006; status: completed.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2006-001709-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001709-27.